“We would go upstream to look at the prevention side and slow the progression from CKD stage 1 to stage 5,” group CEO Rohit Singh told ET in an exclusive interview. “The idea is to have a mass scale screening aggregated at some place; then we use data to categorise the people and predict and give them a medical management plan which can be supervised by a nephrologist.”
The Hyderabad-based company plans to roll out the data science-driven platform within the next two to three years.
While “dialysis will continue to remain the core,” the broader ambition is to become “a true multinational dialysis delivery organisation…and at some point of time, be a good renal solutions organisation in the delivery space,” Singh said. Nearly 220,000 patients develop end-stage renal disease (ESRD) annually in India, leading to an additional annual dialysis demand of 34 million treatment sessions, according to an EY-NatHealth study.
NephroPlus, which recently went public, operates 524 clinics, including 468 in India and 56 overseas, including the Philippines, Uzbekistan and Nepal. It plans to add 40-50 centres annually in India, while also significantly ramping up its global presence. Singh said the company will continue pursuing government partnerships and public-private projects, which remain critical to expanding access to chronic kidney care.
CKD is projected to become the world’s fifth-leading cause of death by 2030. According to estimates, India’s dialysis market remains vastly underserved with only 8-10% people who need dialysis getting the treatment.
“We would be looking at a 15-20% revenue CAGR in the three to four years horizon very comfortably,” Singh said. “Growth will come from three levers-organic growth, deepening in existing geographies by increasing footprints, and opening a new geography of growth, or a large M&A, or a large public-private partnership.”International markets are expected to contribute an increasing share of revenues. Overseas revenue contribution rose to 40% in FY26 from 32% a year earlier. The company is looking at entering Saudi Arabia, while deepening presence in CIS and SE Asia regions. “We will be opening (centres) in one country in a two-year horizon…or one to two countries in a 2-3-year horizon, because it requires intensive study around the geography,” Singh said.
One of the biggest limiting factors to access to dialysis is affordability, he said. “We still have a lot out of pocket and it’s a chronic situation.”
Government-supported dialysis pricing in India is in the range of ₹1,200-2,300 per session, depending on the scheme or state, while private-pay dialysis costs in India are ₹1,500-3,500 per session, with 30-40% still out of pocket.